secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001193125-24-003348
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma appoints new CFO, CMO departs; leadership reshuffled as late-stage program advances
--------------------------------------------------------------------------------

- Michael Carulli promoted to CFO; Winston Kung transitions to advisor through March 2024.
- Leila Alland steps down as CMO; remains advisor through March 2024 at $500/hour.
- Deepika Jalota appointed Chief Development Officer; Marc Fellous named SVP Clinical Development.
- Robert Ticktin expands role to include Operations; Tim Smith adds Corporate Development duties.
- Carulli receives $370K base salary, 40% bonus target, and severance policy coverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312524003348/0001193125-24-003348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312524003348/d104934d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer